Over 4,200 people set to benefit after we reccomend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
We produce useful and usable guidance for the NHS and wider health and care system.
Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Latest from NICE
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
Deal agreed for continued access to life-changing treatment for rare inherited disease
We are consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (CLN2), a type of Batten disease.
Health inequalities - an update to NICE’s methods for health technology evaluation
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
Implementation and planning
Best practice resources for practitioners and commissioners.
More ways we support you
Useful sources of information and advice for healthcare professionals, patients, parents and carers.
Summaries of evidence and advice on common health topics (CKS)
